In the PSMA-targeting TGFβ-insensitive armored CAR T cell trial, the dose of CAR T cells was reduced after high-grade toxicity occurred (sepsis and macrophage activation syndrome/hemophagocytic lymphohistiocytosis). This evidence concerns the gene FOLH1 and macrophage activation syndrome.